Pfizer is paying Innovent $650 million upfront to partner on cancer drug development, following Bristol Myers Squibb by ...

The pharmaceutical outfit has taken a savvy step forward. Now it just needs to repeat the process a few more times.

Investors are clearly worried about the safety of Pfizer's dividend, which is reasonable.

Pfizer has entered a license agreement with Chai Discovery, a company engineering AI models to discover new molecules.

Chai Discovery is working with major drugmakers to use its latest antibody AI model to find new therapies. Now it’s in talks ...

Involving up to 12 antibody drugs, the alliance is the latest broad partnership between Chinese biotech and a multinational pharmaceutical company.

Pfizer CEO Albert Bourla speaks shakes hands with U.S. President Donald Trump in a White House event on Tuesday. President Trump and Pfizer announced a deal to cut drug pricing yesterday. And it looks ...

Pfizer $4.9 billion cash acquisition of Metsera, a clinical-stage biotech focused on next-generation obesity drugs, is more than another high-profile deal in pharma’s dealmaking spree. It signals a ...

Fresh off the acquisition of metabolic medicines developer Metsera, Pfizer is again turning to dealmaking to expand its obesity drug pipeline, this time picking up an experimental oral drug that could ...

As noted, Merck and Pfizer are both large pharmaceutical companies. Making and selling drugs is complex, expensive, and competitive. There are massive research and development costs involved in ...

Novo's $10 billion offer deemed superior by Metsera Pfizer files lawsuits against Metsera and Novo Nordisk Pfizer raises 2025 profit forecast amid declining COVID-19 sales Delaware Judge suggests ...